Sirnaomics begins Phase IIa trial of STP705 to treat hypertrophic scar

Biopharmaceutical company Sirnaomics has initiated the Phase IIa trial of its small interfering RNA (siRNA) therapeutic candidate STP705 (Cotsiranib) to treat patients with hypertrophic scar.

Source: Drug Development Technology - February 7, 2017 Category: Pharmaceuticals Source Type: news